Drug intelligence / Profile preview

anti-CD7 CAR-T

Development stage: Phase 1
Lead developer: Guangzhou Bio-gene Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

anti-CD7 CAR-T is a chimeric antigen receptor (CAR) T-cell therapy designed to target the CD7 protein found on T-cell lymphoblastic acute leukemia/lymphoma cells. Developed by Guangzhou Bio-gene Technology Co., Ltd, this autologous cell therapy involves genetically modifying a patient's own T-cells to express a CAR that recognizes and binds to CD7, leading to the destruction of cancerous cells. It is currently being investigated for its safety and efficacy in treating patients with relapsed or refractory T cell lymphoblastic acute leukemia/lymphoma.

Other names: CD7 CAR-TCD-7 CAR-TCD 7 CAR-T靶向CD7的CAR-T细胞

Targets

CD7 (CD7 antigen)

Beyond the preview

Go deeper on anti-CD7 CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD7 CAR-T.

Explore the full profile